Royalty Report: Drugs, Arthritis, Disease – Collection: 227285

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Arthritis
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Immune
  • Pain
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 227285

License Grant
The English parties agree to a collaboration for the further development, manufacture and commercialization of the Product initially for the treatment of rheumatoid arthritis (‘RA’) and Crohn’s disease in humans and for the treatment of any other agreed indications in the Field.  The co-exclusive collaboration includes the right to appoint any third party including but not limited to affiliated companies as distributors, except for Japan where Licensee shall have the right to appoint sub-licensees.
License Property
Product means Licensor’s anti-TNFµ compound known as CDP-870 in any formulation and indication.
Field of Use
The licence is exclusive for rheumatoid arthritis and other indications, excluding Crohn's disease.

IPSCIO Record ID: 42526

License Grant
Under the Supplement Agreement, the company and Licensee each granted the other party, in the other party’s territory, exclusive, royalty-bearing licenses under certain patent rights and know-how to develop, manufacture and commercialize BOW070. Licensee’s territory consists of China, Hong Kong, Macau and Taiwan, and the Company’s territory consists of the rest of the world.
License Property
This Supplement adds the proprietary product, BOW070 (tocilizumab), a biosimilar version of ActemraTM, an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis (“BOW070”), as a New Collaboration Compound to the Collaboration Agreement. In the Collaboration agreement the parties have agreed to jointly develop and commercialize up to five (5) Collaboration Compounds, as determined by both parties.

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

IPSCIO Record ID: 26092

License Grant
The Compny announced that it had reached a settlement agreement.
License Property
Humira(R) is licensed to Licensee, is the first Licensor-derived antibody to be approved for marketing. It was isolated and optimized in collaboration with Licensee and has been approved for marketing as a treatment for rheumatoid arthritis (RA) in 57 countries, and for Psoriatic arthritis and early RA in some European countries and the US.

Humira (adalimumab) is a fully human anti-TNFa monoclonal antibody, isolated and optimized by Licensor in collaboration with Licensee and now approved for marketing as a treatment for rheumatoid arthritis or RA, early RA and Psoriatic arthritis.  Humira (adalimumab) is Licensor's only marketed product, approved as a rheumatoid arthritis treatment.

IPSCIO Record ID: 210065

License Grant
The Belgium Licensor granted the China Licensee an exclusive, royalty-bearing license to develop and commercialize the anti-TNF alpha Nanobody, ozoralizumab, and certain other anti-TNF alpha Nanobodies in Greater China for all indications, including rheumatiod arthritis.
License Property
The Licensors anti-TNF alpha Nanobody, ozoralizumab, targets RA, a progressive inflammatory disease of the joints and surrounding tissues.
Field of Use
The Licensee will be responsible for the registration and commercialization in Greater China of licensed products.

IPSCIO Record ID: 289928

License Grant
The Company entered a joint venture with Chinese Licensor to further develop and commercialize ONS-3010 with Licensor in the agreed countries.
License Property
The Phase I ONS-3010 trial demonstrated pharmacokinetic (PK) bioequivalence on the primary and secondary endpoints for the biosimilar candidate and the US and EU originator product (Humira).

ONS-3010 is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Humira, the reference product for ONS-3010, is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Field of Use
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

IPSCIO Record ID: 210030

License Grant
The Belgium Licensor entered into an exclusive license agreement with Japanese Licensee for the development and commercialization of anti-TNF alpha Nanobody, ozoralizumab, for the treatment of RA in Japan. The Licensee will be responsible for the development, registration and commercialization of ozoralizumab.
License Property
Ozoralizumab is a TNF alpha blocker being developed for the treatment of auto-immune disorders with an initial focus on RA.
Field of Use
The Japanese Licensee is planning to initiate a Phase III trial in RA patients in Japan with ozoralizumab in 2018.

IPSCIO Record ID: 286023

License Grant
The Licensor of England grants a right and license to develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products for use in the Field in the Territory.  

The license s exclusive or non-exclusive on a patent by patent basis.

License Property
Licensor has a product, known as Cxx-870, which contains a recombinant humanized pegylated Fab’ antibody fragment which binds to TNF alpha, or Tumor Necrosis Factor? alpha.

Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.

The patents are titled Multichain Polypeptides or Proteins and Processes for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System;  Process for obtaining Antibodies; Monovalent Antibody Fragments;  and, Biological Products.

Field of Use
Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals; provided, however, that with respect to CDP-571, the Field shall not include the prevention, treatment, diagnosis or control of any diseases or conditions other than rheumatoid arthritis.

IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.

RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.

IPSCIO Record ID: 256265

License Grant
The Licensor of Germany grants to the Licensee of Iceland the following Licenses and rights
–   regarding patents
–  –   an exclusive License for the Territory to perform research, to make, have made, develop, sell, have sold and use the Compound in the Field.
–  –   an exclusive License for the Territory, to develop, to register, to make, have made, use, import, sell and have sold Products in the Field.
–  regarding Know-How
–  –  an exclusive License for the Territory to make, have made, develop, sell, have sold and use the Compound and Product in the Field.
License Property
The licensed compound is the pharmaceutically active compound R-(-)-2-[4-quinolin-2-yl-methoxy)-phenyl]-2-cyclopentyl acetic acid] having the molecular formula C23H23N03.  The products are any that incorporate the compound.
Field of Use
The Field shall mean the use of Product for the inhibition of leukotrienes in humans in connection with the prevention or treatment of any condition or indication, e.g. for treatment of inflammatory diseases such as Asthma, rheumatoid arthritis and inflammatory Bowel disease, etc.

IPSCIO Record ID: 76567

License Grant
We have a worldwide license and collaboration agreement which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases.
Field of Use
This agreement pertains to the drug industry relating to inflammatory and autoimmune diseases.

IPSCIO Record ID: 51256

License Grant
This Supplement between a Chinese Licensor and Swiss Licensee adds the proprietary product, BOW070 (tocilizumab),  as a New Collaboration Compound to the Collaboration Agreement.  The agreement covers the initial Product Development Plan for BOW070 through Pre-Clinical Development and the Licensor may be a Preferred Supplier of the New Collaboration Compound of clinical and commercial supply subject to meeting quality requirements set forth in product specifications, and cGMP compliance of the destination countries.
License Property
Biosimilar Tocilizumab (BOW 070/LZM 008) is a biosimilar version of ActemraTM, an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis.

IPSCIO Record ID: 231728

License Grant
The Licensor granted the Bermudan Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. a human monoclonal antibody for the treatment of rheumatoid arthritis.
License Property
The Licensor also granted reference rights to relevant manufacturing and regulatory documents and existing supply of mavrilimumab drug substance and product.
Field of Use
The Bermudan Licensee is obligated to use commercially reasonable efforts to develop and commercialize the licensed products.  The investigational drug may be used as a rheumatoid arthritis treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.